Company intelligence / Profile preview

Flash Therapeutics

Toulouse, Occitanie, Franceflashbiosolutions.com ↗

Ownership: Private
Employees: ~39
Development stage: Other

Overview

Flash Therapeutics provides GMP-compliant viral vector manufacturing for advanced therapies. Their proprietary platforms support a range of cell and gene therapy applications. They have received grants for COVID vaccine development and expanded their biomanufacturing capacity in recent years. No direct clinical trial results as they are a service provider.

Modalities: Gene therapyRNA therapyDNA therapyViral vector-based therapy
Industry: Contract Manufacturing Organization

Drug pipeline

1 asset

UCART20x22

IND

Indications: Relapsed/refractory B-cell lymphoma

Partnerships

CEA – Institut de biologie François Jacob/Laboratoire de Génomique et Radiobiologie de la Kératinopoïèse (LGRK) – long-term collaboration on skin stem cell research with plans to expand partnership.

Beyond the preview

Go deeper on Flash Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Flash Therapeutics.